Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model.
about
Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum DisorderDysregulation and restoration of translational homeostasis in fragile X syndromeEmerging pharmacologic treatment options for fragile X syndromeThe contribution of inhibitory interneurons to circuit dysfunction in Fragile X SyndromeTreatment of neurodevelopmental disorders in adulthoodTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesReview of targeted treatments in fragile X syndromeEvaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autismUsing mouse models of autism spectrum disorders to study the neurotoxicology of gene-environment interactionsGABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.Progress toward therapeutic potential for AFQ056 in Fragile X syndrome.The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.From FMRP function to potential therapies for fragile X syndrome.Modeling fragile X syndrome in the Fmr1 knockout mouseFragile X syndrome: a review of clinical and molecular diagnoses.Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.Fragile X targeted pharmacotherapy: lessons learned and future directions.Modulation of the GABAergic pathway for the treatment of fragile X syndrome.A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency.Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients.Psychosis and catatonia in fragile X: Case report and literature review.MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndromeThe translation of translational control by FMRP: therapeutic targets for FXS.Molecular medicine of fragile X syndrome: based on known molecular mechanisms.Cortical interneuron dysfunction in epilepsy associated with autism spectrum disorders.Pharmacotherapy for Fragile X Syndrome: Progress to Date.GABAergic circuit dysfunction in the Drosophila Fragile X syndrome model.Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.Developing BACE-1 inhibitors for FXS.A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome.Deletion of Fmr1 results in sex-specific changes in behaviorDecreased surface expression of the δ subunit of the GABAA receptor contributes to reduced tonic inhibition in dentate granule cells in a mouse model of fragile X syndrome.Of Men and Mice: Modeling the Fragile X Syndrome.Fragile X syndrome: From protein function to therapy.
P2860
Q26781265-118011D6-E54F-4ACF-8447-BCE04C7E24B1Q26782616-3D139E7E-49F5-4DD1-9907-8B7AD145DEDFQ26829152-939721FB-4967-4D96-985E-0B4F1400BA6FQ26998540-F37DC092-2773-4CBD-A749-F970B866C1DBQ27000307-25489FAD-C622-4A8D-8589-2F2662947631Q27023257-81C2BA08-740D-4686-B427-BB53639070ECQ28077180-8C0EF421-C6F0-40F3-9207-8AE86DCF2C6EQ28383216-4BA66B9D-9C85-4349-A1F9-20B41E5A3DABQ28392778-4F162E60-0690-47B7-B50A-95C0319BA498Q30363617-B5BB37DD-1B88-4532-827E-AE9FF759796BQ30383696-BE2F61CB-450C-4668-89DF-ACAF2E1A2423Q30385019-669BA2F9-5E0F-4BAE-9D60-F0D5313836B6Q30410502-36270FE9-5523-4ACF-A646-9F6D779627D1Q30420595-0D8C9ED7-9DD9-494C-9A81-596C3885C5BDQ33576328-2B768170-F8EB-41FC-94E3-4493D5F8F699Q33659830-1DD517BC-0984-4204-9E4B-E2BCAB53D6D9Q33785983-69AE1AC9-9102-4A96-BD4D-EAD439013C6CQ34230612-6DEA9893-7D10-45A2-A9E2-B6B8913BFAF8Q34392818-6B5C2DFC-5816-4002-87DF-897376FB5FF4Q34482877-2F6994AE-6314-4B7A-A14A-2839682DA171Q35723110-8349BB92-F6B1-4E88-8C5A-5DC73EE1FB0CQ35771116-C3D8E12F-B5C0-474E-9475-E3288D777978Q37198789-8E01830B-BF62-4965-98A0-EACBC4042EBDQ38098906-D23409A8-71BA-4AD7-8B9D-14B9728EDD46Q38627691-EB2AB5E3-7637-4852-8E55-CF2C48690ED9Q38673371-ADD2E4FD-6DEA-4487-BDC4-B9B813F31B4CQ38726962-FF7D5F0E-F7C5-4007-B993-FD231B9029E3Q38787519-8077293C-492A-4E65-BF9E-C64F237B8355Q39462489-8387F01F-2DB2-4BB5-9DEF-7CFC7858F584Q41073215-540E1AF7-E9CE-40FC-99DB-09791134A429Q41215871-1CEC13F1-9C6C-4DF4-B9CE-0B5144EBE74FQ42655986-D9840A48-61D8-4F68-A01E-9FB88F7FA914Q45011378-C111251D-6493-491D-9CC6-2AEE4E97AF93Q53422584-C2AD4607-5B86-4F0F-B116-BE6280031F83Q54782597-30FF9481-CC72-4A62-8C28-7A24D779A3E4
P2860
Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Pharmacological treatment of f ...... ugs in a knockout mouse model.
@en
Pharmacological treatment of f ...... ugs in a knockout mouse model.
@nl
type
label
Pharmacological treatment of f ...... ugs in a knockout mouse model.
@en
Pharmacological treatment of f ...... ugs in a knockout mouse model.
@nl
prefLabel
Pharmacological treatment of f ...... ugs in a knockout mouse model.
@en
Pharmacological treatment of f ...... ugs in a knockout mouse model.
@nl
P2093
P1476
Pharmacological treatment of f ...... ugs in a knockout mouse model.
@en
P2093
Charlotte D'Hulst
Debby Van Dam
Inge Heulens
Peter P De Deyn
P304
P356
10.1016/J.BBR.2012.01.031
P407
P50
P577
2012-01-21T00:00:00Z